The estimated Net Worth of Christiana Stamoulis is at least $14.6 Million dollars as of 17 July 2024. Ms. Stamoulis owns over 9,039 units of Incyte stock worth over $3,441,279 and over the last 14 years she sold INCY stock worth over $6,646,449. In addition, she makes $4,495,670 as Chief Financial Officer and Executive Vice President at Incyte.
Christiana has made over 10 trades of the Incyte stock since 2013, according to the Form 4 filled with the SEC. Most recently she exercised 9,039 units of INCY stock worth $241,703 on 17 July 2024.
The largest trade she's ever made was selling 83,000 units of Incyte stock on 29 April 2013 worth over $6,598,500. On average, Christiana trades about 3,334 units every 80 days since 2011. As of 17 July 2024 she still owns at least 54,511 units of Incyte stock.
You can see the complete history of Ms. Stamoulis stock trades at the bottom of the page.
Christiana Stamoulis has been appointed as Chief Financial Officer, Executive Vice President of the company effective February 11, 2019. She as served as President since February 2018 and Chief Financial Officer since January 2015 of Unum Therapeutics Inc., a biopharmaceutical company, and has resigned from those roles effective January 31, 2019. From January 2014 until she joined Unum, Ms. Stamoulis was an independent advisor to biopharmaceutical companies. From 2009 until December 2013, Ms. Stamoulis was a Senior Vice President of Corporate Strategy and Business Development at Vertex Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Vertex, Ms. Stamoulis spent nearly 15 years in the investment banking and management consulting industries. She was a Managing Director in the Investment Banking division of Citigroup and, prior to that, she was a senior investment banker in the Healthcare Investment Banking Group of Goldman, Sachs & Co., where she spent the majority of her investment banking career. Ms. Stamoulis started her career as a strategy consultant at The Boston Consulting Group. Ms. Stamoulis has served as a member of the board of directors of Hologic Inc., a medical technology company, since November 2011. Ms. Stamoulis holds two undergraduate degrees from the Massachusetts Institute of Technology (MIT) and an M.B.A. from the MIT Sloan School of Management.
As the Chief Financial Officer and Executive Vice President of Incyte, the total compensation of Christiana Stamoulis at Incyte is $4,495,670. There are 4 executives at Incyte getting paid more, with Herve Hoppenot having the highest compensation of $15,151,200.
Christiana Stamoulis is 49, she's been the Chief Financial Officer and Executive Vice President of Incyte since 2019. There are 23 older and 3 younger executives at Incyte. The oldest executive at Incyte Corp. is Pamela M. Murphy, 70, who is the VP of Investor Relations & Corp. Communications.
Christiana's mailing address filed with the SEC is Campus Drive, Marlborough, Middlesex County, Massachusetts, 01752, United States.
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B..., and Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: